Overview

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Status:
ENROLLING_BY_INVITATION

Trial end date:
2027-08-17

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006.

Phase:

PHASE3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

rozanolixizumab